Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
DURANCEDURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr | |
|---|---|
| Local Project Reference: | 121881 |
| Principal Investigator: | Dr. Mark Linch |
| Drug Class/ Treatment: | Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine) |
| Patient Population: | Non-Muscle Invasive Bladder Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
ABACUS-2ABACUS-2: Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer | |
|---|---|
| Local Project Reference: | 135538 |
| Principal Investigator: | Dr. Mark Linch |
| Drug Class/ Treatment: | Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1) |
| Patient Population: | Patient requiring surgery with:
|
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
